Procedures were performed either under conscious sedation or general anesthesia. Using femoral venous and arterial access, multipolar Background-Catheter ablation for ventricular tachycardia (VT) from structural heart disease has a significant risk of recurrence, but the optimal duration for in-hospital monitoring is not defined. This study assesses the timing, correlates, and prognostic significance of early VT recurrence after ablation.
V entricular tachycardia (VT) is a marker for increased mortality and can reduce quality of life in patients who have implanted cardioverter defibrillators (ICDs) and structural heart disease. 1, 2 Radiofrequency catheter ablation is an accepted therapy to reduce episodes of drug-refractory VT, but recurrences are not uncommon, despite acutely successful ablation. 3, 4 The optimal duration for monitoring in hospital after ablation is not clear. Although hospital stays are often short in uncomplicated patients, we have observed several patients who needed further ablation because of early recurrences. 5 Others have observed that VT, which is not inducible at the end of the procedure, is again inducible within a few days in a substantial number of patients, suggesting lesion healing. 6 It seems likely that there are patients who are at risk for early recurrence and who may benefit from prolonged monitoring for recurrence and consideration of early repeat ablation. The aims of this study were to identify potential markers of early recurrence and assess the prognosis of these patients.
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Methods
Patient Characteristics
A consecutive series of 370 patients (313 men; aged 63.0±13.2 years) who underwent their first radiofrequency ablation for sustained monomorphic VT associated with structural heart disease at our institution from 2008 to 2012 were included. All patients underwent physical examination, 12-lead electrocardiography, chest x-ray film, and transthoracic echocardiography. Estimated glomerular filtration rate (eGFR) was calculated from the chronic kidney disease-epidemiology) creatinine equation. 7 Heart disease was classified as ischemic cardiomyopathy or nonischemic heart disease, including dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, hypertrophic cardiomyopathy, cardiac sarcoidosis, myocarditis, valvular heart disease, and congenital heart disease or unspecified cardiomyopathy. 8 Each patient gave written informed consent. Studies and data collection were performed according to protocols approved by the Human Research Committee of Brigham and Women's Hospital. October 2014 electrode catheters were positioned in the right ventricular apex and the His bundle region. Programmed ventricular stimulation for initiation of VT was performed with ≤3 extrastimuli scanned to refractoriness or a minimum coupling interval of 180 ms, applied after a basic drive of 600 ms and then 400 ms from 2 right ventricular sites and burst pacing. If VT was exercise-related and usually in arrhythmogenic right ventricular cardiomyopathy, programmed stimulation was repeated during intravenous infusion of isoproterenol.
Mapping and ablation was performed using a 3.5-mm-tip open-irrigated catheter (NaviStar ThermoCool; Biosense Webster, Diamond Bat, CA) or with a 4-mm-tip nonirrigated catheter (NaviStar, Biosense Webster). Electroanatomic mapping was performed with the CARTO mapping system (CARTO 3 or XP; Biosense Webster). In the electroanatomic mapping system, bipolar electrograms were high pass-filtered at 20 to 30 Hz and low pass-filtered at 400 Hz. Bipolar electrograms were also bandpass-filtered from 30 to 500 Hz and digitally recorded along with a 12-lead surface electrocardiography using the Cardiolab EP system (General Electric Healthcare, Buckinghamshire, UK). Voltage maps were created during sinus rhythm. Peak-to-peak bipolar electrogram amplitude <0.5 mV was defined as dense scar and voltage ≥0.5 and <1.5 mV as scar border zone. 9 Ablation targeted all inducible sustained monomorphic VTs, initially focusing on clinical VTs or presumptive clinical VTs (if 12lead electrocardiographies were not available) and including slower VTs. Remaining VTs with shorter cycle lengths than the clinical or presumptive clinical VTs were then targeted depending on whether potential substrate areas for these VTs were present and the tolerance of the patient for continuing the procedure as assessed by the treating physician. If VT was hemodynamically tolerated and reproducibly induced, mapping and ablation was performed during VT. Sites were targeted for ablation if pacing entrained the VT with concealed fusion and a postpacing interval within 30 ms of the ventricular tachycardia cycle length 10, 11 or in the absence of entrainment if an isolated middiastolic potential or presystolic potential was present. If VTs were unmappable because of hemodynamic intolerance or poor reproducibility, ablation was guided by substrate mapping during sinus rhythm and limited assessment during VT, targeting presumptive channels and exits within low voltage areas identified from a paced QRS morphology similar to the VT QRS morphology, abnormal fractionated potentials, double potentials, or late potentials during sinus or paced rhythm at sites where pacing captured, particularly with stimulus-QRS intervals of >40 ms. If no low voltage area was identified, ablation was attempted at the likely exit region identified as sites with presystolic electrocardiographies during VT or where pace mapping resembled the VT QRS. Pace mapping and entrainment mapping used unipolar stimuli at 10 mA and at pulse width of 2 ms. 12 Irrigated radiofrequency energy was delivered at a power of 25 to 50 watts, targeting an impedance drop of 10 to 20 ohms. At target ventricular areas (below the aortic valve), applications were usually repeated until unipolar pacing at 10 mA at 2 ms stimulus strength failed to capture. 12 At target areas in the sinuses of Valsalva, power exceeding 35 watts was avoided.
Epicardial mapping was considered if a subepicardial VT origin was suspected based on endocardial mapping either at the same or at a subsequent session. Percutaneous subxiphoid epicardial access was obtained as previously described either before administration of systemic anticoagulation or after anticoagulation was reversed to achieve an activated clotting time of <200 s before attempting pericardial access. 13 At the end of the procedure, the same stimulation protocol was repeated with or without isoproterenol infusion. Acute complete success was defined as the absence of any inducible monomorphic VT. Partial success was defined as abolition of the clinical or presumptive clinical VT, but other VTs remained inducible; these patients were further divided into those with VTs that were faster than clinical VTs (fast VTs inducible) and those with VTs that were still as slow or slower than a clinical VT (slow VT inducible). Acute ablation failure was defined as inability to render a clinical or presumed clinical VT noninducible.
Data Collection and Follow-Up
Data were collected from a centralized system containing records of all patients treated and followed at Brigham and Women's Hospital and all associated Partners Healthcare sites. These records include emergency department visits, outpatient clinic visits, data recorded during inpatient care, as well as follow-up progress notes from referring physicians monitoring out-of-area patients. In addition, referring cardiologists and primary care physicians were contacted for clinical follow-up of their patients if necessary. Early recurrence was defined as spontaneous sustained VT within 7 days of ablation. Mortality was determined by interrogation of the Social Security Death Index.
Statistical Analysis
Continuous variables were expressed as mean±SD values or median, and interquartile ranges are shown in parentheses, as appropriate. Student's t test or Mann-Whitney's U test was used to compare continuous variables, depending on whether the values were normally distributed, and the χ 2 test was used to compare dichotomous variables unless the expected values in any cells were <5, in which case Fisher exact test was used. Multivariable analysis was performed with the use of logistic regression analysis to assess correlates of early recurrence of VT. The following variables with P<0.05 for the comparison between early recurrence group and no early recurrence group were entered into a multivariable model: New York Heart Association (NYHA) ≥III, dilated cardiomyopathy, VT storm defined as ≥3 episodes of VT within 24 hours, oral amiodarone therapy before the hospitalization, left ventricular ejection fraction, eGFR, the number of VT morphologies induced during the procedure, and acute failure or no final induction test at the end of the procedure. The survival curves were created using the Kaplan-Meier method, and comparisons between groups are based on the log-rank test. Cox proportional hazard models were used to assess correlates of all-cause mortality. The following 10 variables that have been previously associated with outcomes 8, 14 were included in the unadjusted model; NYHA ≥III, ischemic cardiomyopathy, left ventricular ejection fraction, eGFR, the number of failed antiarrhythmic drugs (AADs), VT storm, the number of VT morphologies induced during the procedure, acute failure of the procedure and early VT recurrence, and variables with P<0.05 were entered the multivariable Cox hazard model. P<0.05 was considered to be statistically significant. All statistical analyses were performed with JMP 9 software (SAS Institute, Cary, NC).
Results
Baseline Characteristics
Of the 370 patients, 58% had ischemic cardiomyopathy, and the remainder had nonischemic causes of heart disease (Table 1) . During the 7 days after ablation, sustained VT recurred in 81 patients (22%), and 289 (78%) patients were free of recurrence. Over half (54%) of early recurrences were within 48 hours of the procedure (Figure 1 ).
The early recurrence group had more evidence of advanced cardiac failure compared with the no recurrence group by NYHA classification, lower left ventricular ejection fraction, and eGFR (Table 1) . Dilated cardiomyopathy was more frequent in the early recurrence group. More patients in the early recurrence group had a history of VT storm and ICDs. However, there were not statistically significant differences in age, sex, body mass index, the prevalence of hypertension, hyperlipidemia, or diabetes mellitus, history of prior ablation, and ventricular assist device implantation between the 2 groups.
Electrophysiological Study and Ablation
Early recurrence patients had more VT morphologies induced during the procedure; however, other VT characteristics, including the CL and hemodynamic tolerance of inducible VTs, were not different ( Table 2 ). The early recurrence group had longer total radiofrequency application times.
Epicardial ablation tended to be used more frequently in the early recurrence group. Acute complete success was obtained less frequently, and the incidence of acute failure or no induction test after ablation was more frequent in the early recurrence group compared with the no recurrence group. The procedure was terminated because of a complication in 4 patients who had early recurrences and in 7 patients who did not have an early recurrence (P=0.27): cardiac tamponade in 3 patients with early recurrences and in 6 patients without early recurrence, coronary artery occlusion treated with emergent angioplasty in 1 patient with early recurrences, and thrombus formation in the ventricle observed on intracardiac ultrasound without embolization in 1 patient without early recurrence.
Antiarrhythmic Drug Therapy
AAD therapy before hospitalization with amiodarone (65 versus 47%; P=0.004) and mexiletine (31 versus 18%; P=0.01) were more common in the early recurrence group ( Table I in the Data Supplement). The patients were hospitalized or transferred to our institute for a median of 2 (1, 4) days before the ablation procedure in the recurrence group and 2 (1, 3) days in the no recurrence group (P=0.71). During hospitalization before the procedure, intravenous lidocaine was required more frequently to suppress VT (52 versus 28%; P<0.0001) in the early recurrence group, but there was no difference in administration of intravenous amiodarone between 2 groups. After the procedure, more patients resumed oral amiodarone in the early recurrence group than in the no recurrence group (57 versus 43%; P=0.03). Immediately after the procedure, a lidocaine infusion was administered more frequently in the early recurrence group either because of recurrence or in the hope of reducing the chance of an early recurrence at the treating physicians discretion (14 versus 3%; P=0.0009). However, there were no differences in the administration of sotalol or other β-blocker. 
Correlates of Early VT Recurrence
Follow-Up and Mortality
In 58 of 81 early recurrence patients, the morphology of the VT that recurred was available, and VT morphology was similar to the clinical VT morphologies noted before ablation in 27 patients (47%).
A flow chart indicating follow-up details in early recurrence patients is shown in Figure 2 . In the early recurrence group, 44 of 81 (54%) patients underwent repeat ablation during the same hospitalization, and acute complete success was achieved in 17 of 44 (39%) patients. However, 26 of the 44 (59%) patients had further VT recurrence that occurred at a median of 26 (2, 121) days of follow-up, and 13 (30%) patients underwent >3 ablation procedures. The 37 of 81 (46%) patients discharged without repeat ablation were managed with increased AAD in 19 patients, increased β-blocker in 7 patients, no medication change in 8 patients; and 3 patients died. However, 14 of these 37 (38%) patients subsequently had another ablation procedure because of further VT recurrences, despite of medication. Although acute complete success was acquired in 5 of 14 (36%) patients, 8 (57%) patients had further VT recurrence at a median of 103 (7, 432) follow-up days.
Kaplan-Meier curves of all-cause mortality are shown in Figure 3A and 3B. During a median of 2.5 (1.2, 4.0) years of follow-up, the mortality was significantly greater in the early recurrence group (P<0.0001 by log-rank test; Figure 3A) . The 1-year mortality for the early recurrence group was 32%, despite of 9% for no early recurrence group. Within the early recurrence group, the difference in the mortality between the 44 patients who underwent repeat ablation during that hospitalization and patients without early repeat ablation did not reach statistical significance (P=0.85 by log-rank test; Figure 3B ). In Cox, univariable analysis revealed that higher age, NYHA ≥III, lower left ventricular ejection fraction and eGFR, a history of VT storm, the number of VT morphologies induced during the procedure, acute ablation failure, and early VT recurrence associated with mortality. After adjustment for these variables, early VT recurrence remained an independent correlate of mortality (hazard ratio 2.59, 95% CI 1.52-4.34; P=0.0005; Table III in the Data Supplement).
Discussion
Catheter ablation of VT because of heart disease is often challenging. Recurrence rates and mortality during long-term follow-up remain significant, and recurrences have been associated with increased mortality. 3 We found that 20% of patients have early (within 7 days) recurrent VT, most within 48 hours, and these early recurrences were associated with a 2.6-fold increased risk for mortality during longer-term follow-up. The timing and prognostic significance of recurrences has important implications for patient management, including timing of hospital discharge, consideration of repeat ablation procedures, and therapy adjustments, and potentially long-term management strategies. Furthermore, retrospective analysis identified factors associated with increased risk for early recurrence that might be used to individualize the post ablation management.
There are several potential contributors to early recurrences of VT. The VT substrate may not be adequately ablated, perhaps because of anatomic obstacles, and the same VT remains inducible and subsequently recurs. The majority (58%) of patients who had early recurrences either still had an inducible VT after ablation or complete programmed stimulation was not performed at the end of the procedure. However, the majority (71% of the 159 patients) who had an inducible VT or no induction test after ablation did not have an early recurrence. These findings are consistent with the observations of others that programmed stimulation has somewhat limited ability to predict outcome. 6 We also observed, however, that 43% of patients who had an early recurrence did not have any VT inducible at the end of the ablation procedure. Of the 211 patients who had no inducible VT at the end of the procedure, 35 (17%) had an early VT recurrence. There is increasing evidence, from others, that this finding is a favorable marker of outcome. 15, 16 When VT is not inducible at the end of the procedure VT recurrence may indicate healing of ablation lesions. In our series, the morphology of recurrent VT was available in 38 patients in whom at least clinical VT was not inducible at the end of the procedure and was similar to the clinical VT in 19 patients (50%). In some patients, a decrease in AAD effects after ablation because of drug withdrawal or reduction may lead to occurrence of a previously suppressed VT. In 32 of 81 patients (40%) with early VT recurrence, AADs were reduced in dose or withdrawn after the procedure, although there was no difference between the patients with and without the early recurrence (40% versus 46%; P=0.32). A proarrhythmic effect of ablation, with emergence of new reentry circuits as ablation lesions heal, is also theoretically possible.
Early VT recurrences were an independent correlate for mortality, despite the presence of an ICD. Whether mortality is directly related to further VT recurrences is not clear. Recurrent VT may be slow and below the detect rate of the ICD, perhaps contributing to aggravation of heart failure. VT storm may lead to death, despite an ICD. In this study, 45 patients (56%) had early VT recurrence with VT storms. These considerations raise the possibility that further early ablation to attempt to reduce recurrences may improve outcomes. Our patients who had early recurrence treated with repeat ablation during the same hospitalization did not have a statistically better outcome than those who did not have a repeat ablation ( Figure 3B ). However, the approach to early recurrence was not randomized. Patients selected to have repeat ablation were likely sicker and more had VT storm (68 versus 41%; P=0.01). Further study is needed to determine whether more extensive ablation and attempts to achieve complete abolition of inducible VT will improve outcomes. [17] [18] [19] 
Limitations
Although the VT ablation data are collected prospectively, this study was retrospective. Whether the factors associated with early recurrences are adequate correlates requires prospective validation. The definition of early recurrence as within 7 days was selected arbitrarily. The majority of recurrences within the first 30 days were within 48 hours, and there remains a relation to mortality regardless of whether the definition of early recurrence is <3, 10, or 30 days (data not shown). Several biases undoubtedly determine who is referred for VT ablation. In the present study, isolated VT recurrences that did not result in hospitalization and were not detected by referring cardiologists or primary care physicians were not included as an end point during follow-up. Detection of these events in our referral population can be problematic, and isolated VT recurrences may not preclude good long-term control and clinical benefit.
Clinical Implications
VT recurs within 7 days in 22% of patients who are undergoing catheter ablation for VT associated with structural heart disease and is more likely in those with worse NYHA classification, dilated cardiomyopathy, a history of VT storm, a greater number of induced VT morphologies during the procedure, and the acute failure or no final induction test. An early recurrence is associated with a greater mortality during
VT ablation n=370
Recurrence within 7 days n=81
No recurrence within 7 days n=289
Early repeat ablation during the same hospitalization n=44
No early repeat ablation during the same hospitalization n=37
Repeat ablation during follow-up n=14
No further recurrence n=6
Further recurrence n=26 ≥ 3 ablation n=13
Medication n=13
Further recurrence n=8
No further recurrence n=18 follow-up. Whether patients with these risk factors might benefit from longer hospital monitoring and reassessment of drug therapy and possible early repeat ablation or more extensive ablation warrants further investigation.
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